As of December 2020, more than 200,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 300,000 patient-years.1
> 6,000 patients in clinical trials and open-label extension
> 195,000 patients with post-marketing experience
As of December 2020, more than 200,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 300,000 patient-years.1
> 6,000 patients in clinical trials and open-label extension
> 195,000 patients with post-marketing experience
References
1. Roche data on file: 31 December 2020, post-marketing experience; 27 March 2020, clinical trials data cut-off